Presentation on GPDP_Dr Bharat Rout, MoPR (1).pptxAbhijit Dey
Article 243G of the Constitution of India acknowledges Panchayats as institutions of local self-government and mandates them to prepare plans for economic development and social justice.
Gram Panchayat Development Plans (GPDP) to be prepared for effective implementation of flagship schemes/ programmes
Panchayat Development Plans (PDP) must be comprehensive and based on participatory process, which inter alia involves the full convergence of the schemes of Central and State Governments related to 29 subjects
Intermediate/Block and District Panchayats are responsible for preparing Block Panchayat Development Plan (BPDP) and District Panchayat Development Plan (DPDP) at the respective levels.
As a result, Panchayats envisage for an efficient and robust planning process as part of GP’s core functioning
Overview of TB Mukt Panchayat initiative 30082023-Dr Mrigen.pptxAbhijit Dey
‘Healthy Villages’ has been articulated in achieving Sustainable Development Goals in Panchayat Raj Institutions.
Health functionaries at the village and Sub-Centre/HWC levels along with the support of Gram Panchayats, are making substantial progress towards elimination of TB.
The efforts made need to be measured and validated through a certification process so that panchayats can be declared TB Free.
The certification process will motivate and empower the Panchayats to prioritize and undertake the implementation of program activities.
1. Tuberculosis infection is highly prevalent in India, with an estimated 35-40 crore people infected, and 26 lakh estimated to develop TB disease annually. 2% of household contacts of active TB patients in a recent Indian study developed TB disease within 2 years.
2. Targeted testing for TB infection and provision of preventive treatment can significantly reduce the risk of developing active TB, by 60% on average and up to 90% for people living with HIV. Effective implementation of preventive treatment could reduce annual TB incidence in India by 8.3% based on modeling.
3. The National TB Elimination Program in India has issued guidelines for programmatic management of TB preventive treatment to help reduce
This document discusses India's progress and targets for ending TB. It provides the following information:
1. India's TB burden has declined slightly from 2015-2021 but remains high, with over 5 lakh deaths annually. The percentage of missed cases has reduced from 39% in 2015 to 28% in 2021.
2. India has committed to reducing TB deaths by 90% and incidence by 80% by 2025 compared to 2015 levels as part of its End TB strategy. It aims for zero families facing catastrophic costs due to TB by 2025.
3. Updates are provided on the four pillars - detect, treat, prevent, build - of India's National Strategic Plan to reach these targets, including new
National TB Elimination Programme in India aims to eliminate TB by 2025. TB remains a major public health problem in India, being one of the leading causes of death. In 2019, the estimated TB incidence was 26.4 lakh cases and estimated deaths were 4.45 lakh. There is a large gap between estimated cases and cases notified to the government. Private sector notification is very low. The government's targets are to reduce TB deaths by 90% and cut incidence rate by 80% by 2025 compared to 2015. This will require detecting all TB cases, ensuring treatment completion, preventive measures like contact screening, and building strong public-private partnerships.
- WHO reviewed new evidence on the treatment of drug-resistant tuberculosis which informed updated guidelines.
- For eligible MDR-TB patients, a shorter all-oral regimen containing bedaquiline was found to have better outcomes than regimens containing injectables and may replace them.
- A novel 6-9 month regimen called BPaL showed high success for XDR-TB patients but requires more evaluation due to limited data and side effects before broad implementation.
- The 2020 WHO guidelines will provide more detailed recommendations incorporating this new evidence.
Small PPT on How to measure QT & How to calculate corrected QT.
To get value of cube root of RR(in second) please use google online calculator (search bar) or a scientific calculator
India accounts for about a quarter of global tuberculosis cases, with an estimated 2.79 million new cases and over 4.5 lakh deaths in 2016 alone. Tuberculosis remains one of the top 10 causes of death worldwide and has devastating health and economic impacts, with over 1 lakh women rejected by their families each year due to stigma and 3 lakh children dropping out of school due to their parents having tuberculosis. Risk factors for active tuberculosis include HIV/AIDS, malnutrition, diabetes, smoking, and alcoholism.
Presentation on GPDP_Dr Bharat Rout, MoPR (1).pptxAbhijit Dey
Article 243G of the Constitution of India acknowledges Panchayats as institutions of local self-government and mandates them to prepare plans for economic development and social justice.
Gram Panchayat Development Plans (GPDP) to be prepared for effective implementation of flagship schemes/ programmes
Panchayat Development Plans (PDP) must be comprehensive and based on participatory process, which inter alia involves the full convergence of the schemes of Central and State Governments related to 29 subjects
Intermediate/Block and District Panchayats are responsible for preparing Block Panchayat Development Plan (BPDP) and District Panchayat Development Plan (DPDP) at the respective levels.
As a result, Panchayats envisage for an efficient and robust planning process as part of GP’s core functioning
Overview of TB Mukt Panchayat initiative 30082023-Dr Mrigen.pptxAbhijit Dey
‘Healthy Villages’ has been articulated in achieving Sustainable Development Goals in Panchayat Raj Institutions.
Health functionaries at the village and Sub-Centre/HWC levels along with the support of Gram Panchayats, are making substantial progress towards elimination of TB.
The efforts made need to be measured and validated through a certification process so that panchayats can be declared TB Free.
The certification process will motivate and empower the Panchayats to prioritize and undertake the implementation of program activities.
1. Tuberculosis infection is highly prevalent in India, with an estimated 35-40 crore people infected, and 26 lakh estimated to develop TB disease annually. 2% of household contacts of active TB patients in a recent Indian study developed TB disease within 2 years.
2. Targeted testing for TB infection and provision of preventive treatment can significantly reduce the risk of developing active TB, by 60% on average and up to 90% for people living with HIV. Effective implementation of preventive treatment could reduce annual TB incidence in India by 8.3% based on modeling.
3. The National TB Elimination Program in India has issued guidelines for programmatic management of TB preventive treatment to help reduce
This document discusses India's progress and targets for ending TB. It provides the following information:
1. India's TB burden has declined slightly from 2015-2021 but remains high, with over 5 lakh deaths annually. The percentage of missed cases has reduced from 39% in 2015 to 28% in 2021.
2. India has committed to reducing TB deaths by 90% and incidence by 80% by 2025 compared to 2015 levels as part of its End TB strategy. It aims for zero families facing catastrophic costs due to TB by 2025.
3. Updates are provided on the four pillars - detect, treat, prevent, build - of India's National Strategic Plan to reach these targets, including new
National TB Elimination Programme in India aims to eliminate TB by 2025. TB remains a major public health problem in India, being one of the leading causes of death. In 2019, the estimated TB incidence was 26.4 lakh cases and estimated deaths were 4.45 lakh. There is a large gap between estimated cases and cases notified to the government. Private sector notification is very low. The government's targets are to reduce TB deaths by 90% and cut incidence rate by 80% by 2025 compared to 2015. This will require detecting all TB cases, ensuring treatment completion, preventive measures like contact screening, and building strong public-private partnerships.
- WHO reviewed new evidence on the treatment of drug-resistant tuberculosis which informed updated guidelines.
- For eligible MDR-TB patients, a shorter all-oral regimen containing bedaquiline was found to have better outcomes than regimens containing injectables and may replace them.
- A novel 6-9 month regimen called BPaL showed high success for XDR-TB patients but requires more evaluation due to limited data and side effects before broad implementation.
- The 2020 WHO guidelines will provide more detailed recommendations incorporating this new evidence.
Small PPT on How to measure QT & How to calculate corrected QT.
To get value of cube root of RR(in second) please use google online calculator (search bar) or a scientific calculator
India accounts for about a quarter of global tuberculosis cases, with an estimated 2.79 million new cases and over 4.5 lakh deaths in 2016 alone. Tuberculosis remains one of the top 10 causes of death worldwide and has devastating health and economic impacts, with over 1 lakh women rejected by their families each year due to stigma and 3 lakh children dropping out of school due to their parents having tuberculosis. Risk factors for active tuberculosis include HIV/AIDS, malnutrition, diabetes, smoking, and alcoholism.
Rntcp brief note for ppm coordinators final draft 21 05 18Abhijit Dey
Here are the answers to the pre-test questions:
1. B - TB is not mainly sexually transmitted. It is an airborne infectious disease.
2. D - Convulsion and sudden numbness are not symptoms of TB. The most common symptoms are cough and fever lasting more than 2 weeks, weight loss.
3. D - BCG vaccination at birth does not provide total lifelong protection against TB. It provides some protection, especially against severe forms in childhood.
The purpose of this pre-test is to assess the participants' existing knowledge on basic concepts of tuberculosis prior to the training. The post-test at the end will help evaluate how much they have learned from the training.
Every person in India with symptoms of tuberculosis such as cough lasting more than two weeks, fever for more than two weeks, significant weight loss, or abnormalities on a chest x-ray should be evaluated for TB, as should children with persistent fever or cough lasting more than two weeks, weight loss or lack of weight gain, or contact with a pulmonary TB case. Notifying health authorities of every TB case initiated on anti-TB drugs is important to help conquer the disease, which kills one Indian every minute.
Facilitor's guide for cv training draft1Abhijit Dey
This document provides training materials for community volunteers on tuberculosis (TB) including:
1. Basic information about TB such as what it is, how it spreads, and its magnitude in India with over 28 lakh new cases annually and 1.2 lakh deaths daily.
2. Classification of TB into pulmonary TB affecting the lungs and extra-pulmonary TB affecting other parts of the body.
3. Signs and symptoms of TB and how it is diagnosed using sputum smear microscopy, chest X-ray, and Cartridge Based Nucleic Acid Amplification Test (CBNAAT).
4. Details on India's Revised National Tuberculosis Control Programme (RNTCP)
This document outlines 10 standards for tuberculosis care in India. It summarizes World Health Organization tuberculosis reports from 2016 and 2017, showing declines in TB incidence and mortality. It provides guidelines on testing and screening for pulmonary and extra-pulmonary TB, diagnostic tools, treatment regimens for drug-sensitive and drug-resistant TB, and monitoring treatment response. Standards cover appropriate testing, diagnosis of HIV and drug-resistant TB, pediatric TB diagnosis, first-line and multi-drug resistant treatment regimens, and addressing TB among people living with HIV.
Rntcp brief note for ppm coordinators final draft 21 05 18Abhijit Dey
Here are the answers to the pre-test questions:
1. B - TB is not mainly sexually transmitted. It is an airborne infectious disease.
2. D - Convulsion and sudden numbness are not symptoms of TB. The most common symptoms are cough and fever lasting more than 2 weeks, weight loss.
3. D - BCG vaccination at birth does not provide total lifelong protection against TB. It provides some protection, especially against severe forms in childhood.
The purpose of this pre-test is to assess the participants' existing knowledge on basic concepts of tuberculosis prior to the training. The post-test at the end will help evaluate how much they have learned from the training.
Every person in India with symptoms of tuberculosis such as cough lasting more than two weeks, fever for more than two weeks, significant weight loss, or abnormalities on a chest x-ray should be evaluated for TB, as should children with persistent fever or cough lasting more than two weeks, weight loss or lack of weight gain, or contact with a pulmonary TB case. Notifying health authorities of every TB case initiated on anti-TB drugs is important to help conquer the disease, which kills one Indian every minute.
Facilitor's guide for cv training draft1Abhijit Dey
This document provides training materials for community volunteers on tuberculosis (TB) including:
1. Basic information about TB such as what it is, how it spreads, and its magnitude in India with over 28 lakh new cases annually and 1.2 lakh deaths daily.
2. Classification of TB into pulmonary TB affecting the lungs and extra-pulmonary TB affecting other parts of the body.
3. Signs and symptoms of TB and how it is diagnosed using sputum smear microscopy, chest X-ray, and Cartridge Based Nucleic Acid Amplification Test (CBNAAT).
4. Details on India's Revised National Tuberculosis Control Programme (RNTCP)
This document outlines 10 standards for tuberculosis care in India. It summarizes World Health Organization tuberculosis reports from 2016 and 2017, showing declines in TB incidence and mortality. It provides guidelines on testing and screening for pulmonary and extra-pulmonary TB, diagnostic tools, treatment regimens for drug-sensitive and drug-resistant TB, and monitoring treatment response. Standards cover appropriate testing, diagnosis of HIV and drug-resistant TB, pediatric TB diagnosis, first-line and multi-drug resistant treatment regimens, and addressing TB among people living with HIV.
2. MPW)
(Revised as per Technical Operational Guideline for
TB Control-2016 & Revised PMDT Guideline-2017)
(Revised: March 2018)
3. RNTCP
RNTCP PMDT
Intensified TB Case Finding)
Annexure I : MPW
Annexure II :
AnnexureIII :
Revised Annexure 15 A Form 11-12
I&II-এর ২৩
Daily Regimens, FDC & Weight Bands 24
Integrated DR-TB algorithm & follow-up protocol 25A & 25B
Patient councelling & community involvement 49A
99DOTs & DBT scheme 51A
RNTCP structure & Key personnels 59
Role play 60-61
4. Some of the common abbreviations used in RNTCP
ACF/ICF Active case findings/intensified case findings
ADR Adverse drug reaction
AE Adverse event
AFB Acid Fast bacilli
AIC Airborne infection control
AIDS Acquired Immune Deficiency Syndrome
ALT Alanine aminotransferase
Am Amikacin
Amx/Clv Amoxicillin/clavulanate
ART Anti-retroviral therapy
AST Aspartate aminotransferase
ATS American Thoracic Society
Bdq Bedaquiline
BPL Below poverty line
CAP Conditional Access Programme
CBNAAT Cartridge Based Nucleic Acid Amplification Test
CEM Cohort event monitoring
Cfz Clofazimine
Clr Clarithromycin
Cm Capreomycin
CMO Chief Medical Officer
CP Continuation phase
CPT Co-trimoxazole preventive therapy
Cs Cycloserine
CTD Central TB Division
CUP Compassionate Use Programme
C-DAC Centre for Development of Advanced Computing
C-DST Culture and Drug Susceptibility Test
CL-HIV Children living with HIV
DAIDS Division of AIDS
DBT Direct Beneficiary Transfer
DCGI Drugs Controller General of India
DDG Deputy Director General
DDS District drug store
DDR-TBC District DR-TB Centre
DG Director General
DGHS Directorate General of Health Services
Dlm Delamanid
DMC Designated microscopy centre
DOT Directly observed treatment
DRT Drug resistance testing
DR-TB Drug-resistant tuberculosis
DR-TBC Drug-Resistant Tuberculosis Centre
DSMC Drug Safety Monitoring Committee
5. DST Drug susceptibility testing
DTO District TB officer
DVDMS Drug & vaccine distribution management system
E Ethambutol
ECG Electrocardiogram
ECHO Extension of Community Health Care Outcomes
EP-TB Extra-pulmonary tuberculosis
EQA External quality assurance
Eto Ethionamide
EU European Union
FDA Food and Drug Administration
FEFO First expiry first out
FL-LPA First line-line probe assay
FO Field Officer
FQ Fluoroquinolone
GLC Green Light Committee
GFATM Global Fund for AIDS, Tuberculosis & Malaria
Gfx Gatifloxacin
GMSD General Medical Stores Depot
GoI Government of India
H Isoniazid
Hh High dose isoniazid
HRCT High resolution CT scan
ICH International Conference on Harmonization
ICT Information communication technology
ICMR Indian Council for Medical Research
IP Intensive phase
Ipm Imipenem
IPAQT Initiative for promoting affordable & quality TB test
IQC Internal Quality Control
IRL Intermediate reference laboratory
ISO International Standard Organization
Km Kanamycin
LC Liquid culture
LFT Liver function test
Lfx Levofloxacin
L J Lowenstein Jensen
LPA Line probe assay
LT Laboratory technician
LTFU Lost to follow up
Lzd Linezolid
MAC Mycobacterium avium complex
MDR-TB Multidrug-resistant TB
Mfx Moxifloxacin
Mfxh High dose Moxifloxacin
6. MGIT Mycobacteria growth indicator tube
MIS Management information system
MO Medical Officer
MoHFW Ministry of Health and Family Welfare
MO-DMC Medical Officer-designated microscopy centre
MO-PHI Medical Officer- peripheral health institute
MO-TC Medical Officer TB control
MOTT Mycobacterium other than tubercle bacilli
MoU Memorandum of understanding
Mpm Meropenem
MPR Mixed pattern resistance
MR Mono resistance
MSS Monthly stock statement
NAAT Nucleic Acid Amplification Test
NABL National accreditation board for laboratories
NDRS National Drug Resistance Survey
NDR-TBC Nodal DR-TB Centre
NGO Non-Government Organization
NGS Next-Generation Sequencing
NHPS National health protection scheme
NHM National Health Mission
NIRT National Institute for Research in Tuberculosis
NITRD National Institute for Tuberculosis and Respiratory Diseases
NRL National reference laboratory
NSP National strategic plan
NTI National TB institute
NTM Non-Tuberculous Mycobacterium
OBR Optimized background regimen
Ofx Ofloxacin
OPD Out Patient Department
PAS p-aminosalicylic acid
Pdx Pyridoxine
PDR Poly drug resistance
PHI Peripheral health institute
PK/PD Pharmacokinetic/pharmacodynamics
PL-HIV People living with HIV
PMDT Programmatic management of drug-resistant tuberculosis
PP Private Provider
PQC Product quality compliance
PSM Procurement and supply management
PT Previously treated
PTE Pre-treatment evaluation
Pto Protionamide
PvPI Pharmaco-vigilance programme of India
QA Quality assurance
7. QSE Quality System Elements
R Rifampicin
RNTCP Revised National Tuberculosis Control Programme
RR-TB Rifampicin-resistant tuberculosis
R&R Recording & reporting
RT-MERM Real time medication event reminder monitor device
S Streptomycin
SA Statistical Assistant
SAE Serious adverse event
SDG Sustainable Development Goals
SDS State drug store
SLD Second line anti-TB drugs
SLDST Second line drug susceptibility testing
SLI Second line injectable
SL-LPA Second line-line probe assay
SME Supervision, Monitoring & Evaluation
SoP Standard operating procedures
SPC Specimen Processing Control
STLS Senior TB Laboratory Supervisor
STO State TB Officer
STR Standardized treatment regimen
STS Senior treatment supervisor
TALFU Treatment after lost to follow up
TA Touch Agent
TAT Turn-around time
TB Tuberculosis
TBHV TB Health Visitor
THALI TB Health Action Learning Initiative
Thz Thioacetazone
ToR Terms of reference
Trd Terizidone
TU TB Unit
UDST Universal Drug Susceptibility Testing
ULN Upper limit of normal
UPT Urine pregnancy test
USAID United States Agency for International Development
USFDA United States Food & Drug Administration
WCO World Health Organization Country Office for India
WHO World Health Organization
WHP World Health Partners
XDR-TB Extensively-drug resistant TB
Z Pyrazinamide
29. 21
PHI
CAT II
Prolongation IP)
Cat I m¡m 24 12 18 54
Cat II e£m 36 12 22 66
Prolongation Pouch
Anti TB Regimen- First Line -Standard Tri Weekly regimen for Drug sensitive TB
ea¥e LÉ¡V¡N¢l I 1.ea¥e Øf¥V¡j Øj£u¡l f¢S¢Vi
2.
3.
2HRZE + 4HR
II
1.
f¢S¢Vi
2.
3.
f¢S¢Vi
4. AeÉeÉ
2H R Z E S+1 H R Z E+5 H R E
Intermittent)
¡N£
¡CX, ¢lg¡j¢f¢pe, f¡ul¡¢Se¡j¡CX, Cb¡j¢hEVm
40. 28
l (Treatment Supporter)
(Annexure 15C)
PHI/CHC
e¡j, hup, APL, BPL,
ll
l
l
-
- ¢Q¢Lvp¡l gm¡gm pC J a¡¢lM ;
- LaSe hÉ¢š² I
INH
-
( Record Remarks)
LÉ¡V I J LÉ¡V II , fË¢a¢ce h¡ p¢hl¡j ü¡ÙÛÉ¢h¢d( Daily or Intermittent Regimen)z
(Record drug administration in intensive phase)
-
o ¢Qq²¢V ¢cez
41. 29
-
p¤¤¢hd¡Se s
I II
I V¡N¢l II
CDST (CBNAAT/LPA)
(Record drug administration and collection in
continuation phase)
p¡jh¡l h¤dh¡l J öœ²h¡l
z Hhw ×
× ×---------------z
- supervised unsupervised O- not taken.
: ( Monitor drug collection and recording)
Cat I
April 22nd
dose
O
23rd
dose
24th
dose
S S
April 22nd
dose
O
23rd
dose
S
24th
dose
S
42. 30
April X
17
S O S X
18
p
April X
16
S O X S X
18
(Patient's TB Identity Card) Annexure 15 D
TU ,
PHI
PHI Update)
Nikshay entry Identity Card)